Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities ...

IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial ...

The average one-year price target for Beta Bionics (NasdaqGM:BBNX) has been revised to $20.99 / share. This is a decrease of ...

Irvine-based medical device company Beta Bionics Inc. reports first quarter earnings and raise full-year revenue guidance.

The consensus estimate for Q1 2026 revenue is $26.97 million, and the earnings are expected to come in at -$0.50 per share. The full year 2026's revenue is expected to be $132.59 million, and the ...

Beta Bionics, Inc. BBNX shares rallied 10.3% in the last trading session to close at $13.02. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

The framework I introduced was that when our pharmacy installed base in a given quarter exceeds three times the number of new patient starts through pharmacy in that same quarter, the pharmacy channel ...

Q1 2026 earnings call recap: 57% sales growth, higher 2026 guidance, pharmacy mix gains, and FDA risk updates—read now.